Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis

A technology for taurine chenodeoxycholic acid and osteoporosis, which is applied to medical preparations containing active ingredients, bone diseases, organic active ingredients, etc. Prevention and treatment of osteoporosis and other problems

Inactive Publication Date: 2011-09-07
SHANDONG AGRICULTURAL UNIVERSITY
View PDF3 Cites 35 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The existing methods of prevention and treatment of osteoporosis are generally drug treatment, the commonly used mainly include osteopeptide tablets, calcitonin or alendronate, etc., the above drugs can promote bone growth; there are also direct calcium supplements to fill the bone mass. For the lost part, although the above method has a certain effect, it has the disadvantages of high price of long-term medication or more side effects, and cannot well meet the requirements of prevention and treatment of osteoporosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis
  • Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis
  • Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0013] During the experiment, it was divided into normal group, model group and three administration groups of low dose, middle dose and high dose, with 10 mice in each group. The normal group was only fed with distilled water; the model group was subcutaneously injected with 20 mg / kg dexamethasone, once every other day for 14 days, to prepare the mouse osteoporosis model; For administration, the doses of TCDCA in the administration group were 0.05, 0.1 and 0.2 g / kg, respectively, and the route of administration was intragastric administration, once a day, for 7 consecutive days.

[0014] Blood was collected from the eyeball plexus of the normal group, the model group and the administration group, and the content of osteocalcin in the serum of the mice was detected by radioimmunoassay. The results are shown in Table 1. Compared with the normal group, the low and middle dose groups significantly increased the serum osteocalcin content; compared with the model group, the low, me...

Embodiment 2

[0019] During the experiment, it was divided into normal group, model group and three administration groups of low dose, middle dose and high dose, with 10 mice in each group. The normal group was only fed with distilled water; the model group was subcutaneously injected with 20 mg / kg dexamethasone, once every other day for 14 days, to prepare the mouse osteoporosis model; For administration, the doses of TCDCA in the administration group were 0.05, 0.1 and 0.2 g / kg, respectively, and the route of administration was intragastric administration, once a day, for 7 consecutive days.

[0020] Carry out X-ray film to normal group, model group and administration group mice, see Figure 1-5 . The gray value of the left and right femurs of the mice was measured using ImageJ image analysis software, and the gray value on the X-line can indirectly reflect the bone density. The results are shown in Table 2. It can be seen that compared with the model group, the low, medium and high dos...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to new use of taurochenodeoxycholic acid, in particular to the new use of the taurochenodeoxycholic acid in prevention and treatment of osteoporosis. Through the study on taurochenodeoxycholic acid, the inventor found that the taurochenodeoxycholic acid can promote bone cells to secrete osteocalcin and improve lowered bone density. Thus, the taurochenodeoxycholic acid can beused in prevention or treatment of osteoporosis. After being administrated directly or being formed into various formulations, the taurochenodeoxycholic acid can be used for preventing or treating osteoporosis and other related diseases or states of osteoporosis.

Description

technical field [0001] The invention relates to a new application of taurochenodeoxycholic acid, in particular to a new application of taurochenodeoxycholic acid in preventing and treating osteoporosis. Background technique [0002] Taurochenodeoxycholic Acid (TCDCA) is a conjugated bile acid mainly present in the bile of chickens, ducks, geese, cattle, sheep, snakes and other animals. Its chemical name is 3α, 7α-dihydroxy-5β-24-cholanoyl-N-taurine, and its structural formula is as follows: [0003] [0004] It is an odorless, white powder, extremely bitter acidic compound formed by combining taurine (Tau) and chenodeoxycholic acid (CDCA). The molecular formula is C 23 (OH) 2 h 37 CONHCH 2 CH 2 SO 3 H, the relative molecular mass is 499.69. As a main component of bile, TCDCA has the characteristics of wide range of drug sources, safety and efficacy. Current studies have found that TCDCA has anti-inflammatory (Li Peifeng, Cao Jinshan, Guan Hong, etc. Journal of Chi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/575A61P19/10
Inventor 石有斐李金莲王丛丛李培锋
Owner SHANDONG AGRICULTURAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com